Oligonucleotide Therapy Global Market Report 2025

Description

Oligonucleotide therapy is a comprehensive term encompassing advanced molecular-targeting agents that utilize chemically synthesized oligonucleotides featuring single-stranded DNA (DNA) or RNA (RNA) backbones with inherent selectivity. Oligonucleotides are designed to form base pairs with DNA or RNA strands for various applications, with their most prevalent use being in PCR primers (polymerase chain reaction).

The primary categories of oligonucleotide therapy include antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (AS ONs) are artificial DNA oligomers designed to hybridize with a specific target RNA sequence. They have proven effective in limiting gene expression, modifying precursor messenger RNA splicing, and deactivating microRNAs. This therapeutic approach finds applications in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, among others, and is applied in healthcare facilities and research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The oligonucleotide therapy market research report is one of a series of new reports from The Business Research Company that provides oligonucleotide therapy market statistics, including oligonucleotide industry global market size, regional shares, competitors with an oligonucleotide market share, detailed oligonucleotide therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oligonucleotide industry. This oligonucleotide therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $5.61 billion in 2024 to $6.2 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to growth in investment in research and development, market entry of early therapies, rise of gene editing techniques, early therapeutic discoveries, rnai and antisense oligonucleotide introduction.

The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $9.66 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to research and development investments, global market penetration, therapeutic area expansion, disease modification strategies, regulatory adaptations. Major trends in the forecast period include customized therapies, advancements in delivery systems, rna interference (RNAI) advancements, antisense oligonucleotide innovation, gene editing techniques integration.

The forecast of 11.8% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may hinder U.S. genetic medicine progress by increasing costs of antisense oligonucleotides developed in Japan and the Netherlands, potentially delaying rare disease treatments and raising targeted therapy development expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increase in cancer cases globally is expected to contribute to the oligonucleotide therapy market's growth during the forecast period. For example, as of January 2022, the American Cancer Society projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, averaging around 1,670 fatalities daily. The most prevalent cancer types globally-lung, prostate, bowel, and female breast cancer-constitute 43% of all new cancer cases. Consequently, the surge in global cancer incidence rates is poised to drive the oligonucleotide therapy market's demand in the coming years.

Government initiatives aimed at research and development in healthcare are anticipated to boost the oligonucleotide therapy market's growth. These initiatives involve specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve defined goals, or instigate positive changes in society. Various government bodies are launching healthcare initiatives to support different aspects, including oligonucleotide therapy. In 2022, the UK government, as per the Department of Health and Social Care, committed £260 million (US $270.65 million) in funding to enhance healthcare research and manufacturing. This funding, provided by BEIS and DHSC, aimed to support NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.60 million) was allocated to assist in expanding life sciences manufacturing in the UK.

Developers and providers in the oligonucleotide therapy market are investing in research and development to redesign therapy approaches. Innovative oligonucleotides enable precision medicine, selectively targeting genes with minimal side effects, and addressing patient-specific sequences causing rare diseases. In April 2023, the FDA approved Qalsody, an antisense oligonucleotide (ASO), for treating ALS associated with the SOD1 gene mutation. Qalsody targets SOD1 mRNA to reduce protein synthesis.

Major companies in the oligonucleotide therapy market are introducing pediatric-focused therapies to drive market revenues. Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4 through 5, showcases advancements in gene-based treatments for genetic diseases, although not specifically an oligonucleotide therapy.

In September 2022, Vanda Pharmaceuticals, a US-based biopharmaceutical company, and OliPass, a South Korea-based biotechnology company, announced a strategic partnership to develop antisense oligonucleotide (ASO) therapeutics. This collaboration aims to jointly develop a series of ASO molecules based on OliPass' proprietary modified peptide nucleic acids, leveraging the strengths of both companies to advance ASO-based precision medicine therapeutics.

Major companies operating in the oligonucleotide therapy market include Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Gilead Sciences Inc., BioNTech SE, Moderna Inc., Biogen Inc., Jazz Pharmaceuticals plc, QIAGEN Company, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Dynacure S.A., Arcturus Therapeutics Holdings Inc., Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., Editas Medicine Inc., Evox Therapeutics Ltd., PepGen Ltd.

North America was the largest region in the oligonucleotide therapy market in 2024. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oligonucleotide Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oligonucleotide therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oligonucleotide therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oligonucleotide therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Antisense Oligonucleotide; Aptamer; Other Types
2) By Application: Infectious Diseases; Oncology; Neurodegenerative Disorders; Cardiovascular Diseases; Kidney Diseases; Other End-User
3) By End User: Hospitals; Research Institutes
Subsegments:
1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides; DNA-Targeted Antisense Oligonucleotides; Chemically Modified Antisense Oligonucleotides
2) By Aptamer: DNA Aptamers; RNA Aptamers; Small Molecule Aptamers
3) By Other Types: siRNA (Small Interfering RNA); miRNA (Micro RNA); DNAzyme And Ribozymes; Synthetic Oligonucleotides For Gene Editing
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Gilead Sciences Inc.; BioNTech SE; Moderna Inc.; Biogen Inc.; Jazz Pharmaceuticals plc; QIAGEN Company; Alnylam Pharmaceuticals Inc.; Sarepta Therapeutics Inc.; Ionis Pharmaceuticals Inc.; Akcea Therapeutics Inc.; Arrowhead Pharmaceuticals Inc.; Dicerna Pharmaceuticals Inc.; SomaGenics Inc.; Wave Life Sciences Ltd.; Exicure Inc.; Avidity Biosciences Inc.; Miragen Therapeutics Inc.; ProQR Therapeutics NV; Regulus Therapeutics Inc.; Kastle Therapeutics LLC; Santaris Pharma A/S; InteRNA Technologies B.V.; Dynacure S.A.; Arcturus Therapeutics Holdings Inc.; Intellia Therapeutics Inc.; Regeneron Pharmaceuticals Inc.; Editas Medicine Inc.; Evox Therapeutics Ltd.; PepGen Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r26811u

1. Executive Summary

2. Oligonucleotide Therapy Market Characteristics

3. Oligonucleotide Therapy Market Trends And Strategies

4. Oligonucleotide Therapy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Oligonucleotide Therapy Growth Analysis And Strategic Analysis Framework

5.1. Global Oligonucleotide Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Oligonucleotide Therapy Market Growth Rate Analysis
5.4. Global Oligonucleotide Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Oligonucleotide Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Oligonucleotide Therapy Total Addressable Market (TAM)

6. Oligonucleotide Therapy Market Segmentation

6.1. Global Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antisense Oligonucleotide
Aptamer
Other Types
6.2. Global Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Infectious Diseases
Oncology
Neurodegenerative Disorders
Cardiovascular Diseases
Kidney Diseases
Other End-User
6.3. Global Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Research Institutes
6.4. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Antisense Oligonucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
RNA-Targeted Antisense Oligonucleotides
DNA-Targeted Antisense Oligonucleotides
Chemically Modified Antisense Oligonucleotides
6.5. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Aptamer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
DNA Aptamers
RNA Aptamers
Small Molecule Aptamers
6.6. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
siRNA (Small Interfering RNA)
miRNA (Micro RNA)
DNAzyme And Ribozymes
Synthetic Oligonucleotides For Gene Editing

7. Oligonucleotide Therapy Market Regional And Country Analysis

7.1. Global Oligonucleotide Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Oligonucleotide Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oligonucleotide Therapy Market

8.1. Asia-Pacific Oligonucleotide Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oligonucleotide Therapy Market

9.1. China Oligonucleotide Therapy Market Overview
9.2. China Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oligonucleotide Therapy Market

10.1. India Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oligonucleotide Therapy Market

11.1. Japan Oligonucleotide Therapy Market Overview
11.2. Japan Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oligonucleotide Therapy Market

12.1. Australia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oligonucleotide Therapy Market

13.1. Indonesia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oligonucleotide Therapy Market

14.1. South Korea Oligonucleotide Therapy Market Overview
14.2. South Korea Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oligonucleotide Therapy Market

15.1. Western Europe Oligonucleotide Therapy Market Overview
15.2. Western Europe Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oligonucleotide Therapy Market

16.1. UK Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oligonucleotide Therapy Market

17.1. Germany Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oligonucleotide Therapy Market

18.1. France Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oligonucleotide Therapy Market

19.1. Italy Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oligonucleotide Therapy Market

20.1. Spain Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oligonucleotide Therapy Market

21.1. Eastern Europe Oligonucleotide Therapy Market Overview
21.2. Eastern Europe Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oligonucleotide Therapy Market

22.1. Russia Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oligonucleotide Therapy Market

23.1. North America Oligonucleotide Therapy Market Overview
23.2. North America Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oligonucleotide Therapy Market

24.1. USA Oligonucleotide Therapy Market Overview
24.2. USA Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oligonucleotide Therapy Market

25.1. Canada Oligonucleotide Therapy Market Overview
25.2. Canada Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oligonucleotide Therapy Market

26.1. South America Oligonucleotide Therapy Market Overview
26.2. South America Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oligonucleotide Therapy Market

27.1. Brazil Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oligonucleotide Therapy Market

28.1. Middle East Oligonucleotide Therapy Market Overview
28.2. Middle East Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oligonucleotide Therapy Market

29.1. Africa Oligonucleotide Therapy Market Overview
29.2. Africa Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oligonucleotide Therapy Market Competitive Landscape And Company Profiles

30.1. Oligonucleotide Therapy Market Competitive Landscape
30.2. Oligonucleotide Therapy Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. BioNTech SE Overview, Products and Services, Strategy and Financial Analysis

31. Oligonucleotide Therapy Market Other Major And Innovative Companies

31.1. Moderna Inc.
31.2. Biogen Inc.
31.3. Jazz Pharmaceuticals plc
31.4. QIAGEN Company
31.5. Alnylam Pharmaceuticals Inc.
31.6. Sarepta Therapeutics Inc.
31.7. Ionis Pharmaceuticals Inc.
31.8. Akcea Therapeutics Inc.
31.9. Arrowhead Pharmaceuticals Inc.
31.10. Dicerna Pharmaceuticals Inc.
31.11. SomaGenics Inc.
31.12. Wave Life Sciences Ltd.
31.13. Exicure Inc.
31.14. Avidity Biosciences Inc.
31.15. Miragen Therapeutics Inc.

32. Global Oligonucleotide Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oligonucleotide Therapy Market

34. Recent Developments In The Oligonucleotide Therapy Market

35. Oligonucleotide Therapy Market High Potential Countries, Segments and Strategies

35.1 Oligonucleotide Therapy Market In 2029 - Countries Offering Most New Opportunities
35.2 Oligonucleotide Therapy Market In 2029 - Segments Offering Most New Opportunities
35.3 Oligonucleotide Therapy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer